Dry Eye Syndrome Market to Witness Growth by 2032, Estimates DelveInsight | Companies- TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, St

DelveInsight's "Dry Eye Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Dry Eye Syndrome, historical and forecasted epidemiology as well as the Dry Eye Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Dry Eye Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dry Eye Syndrome market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Dry Eye Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dry Eye Syndrome market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome: An Overview

Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes.

Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes. People with dry eyes may experience irritated, gritty, scratchy or burning eyes; a feeling of something in their eyes; excess watering; and blurred vision. Symptoms include: Redness, stinging, scratching, or burning sensations, light sensitivity, watery eyes, stringy mucus near the eye and a blurry Vision.

Dry eyes can be diagnosed through a comprehensive eye examination. Treatments for dry eyes aim to restore or maintain the normal amount of tears in the eye to minimize dryness and related discomfort and to maintain eye health. The primary approaches used to manage and treat dry eyes include adding tears using over-the-counter artificial tear solutions, conserving tears, increasing tear production, and treating the inflammation of the eyelids or eye surface that contributes to the dry eyes.

Learn more about Dry Eye Syndrome, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome Market

The Dry Eye Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Dry Eye Syndrome market trends by analyzing the impact of current Dry Eye Syndrome therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Dry Eye Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dry Eye Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Dry Eye Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome Epidemiology

The Dry Eye Syndrome epidemiology section provides insights into the historical and current Dry Eye Syndrome patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Dry Eye Syndrome market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Dry Eye Syndrome Epidemiology at: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome Drugs Uptake

This section focuses on the uptake rate of the potential Dry Eye Syndrome drugs recently launched in the Dry Eye Syndrome market or expected to be launched in 2019-2032. The analysis covers the Dry Eye Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Dry Eye Syndrome Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Dry Eye Syndrome market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dry Eye Disease Emerging Drugs

Reproxalap: Aldeyra Therapeutics

Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra's lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

Timbetasin: RegeneRx Biopharmaceuticals

RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

Visomitin: Mitotech

Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

Request for a sample report to understand more about the Dry Eye Syndrome pipeline development activities at: https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome Therapeutics Assessment

Major key companies such as TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others are working proactively in the Dry Eye Syndrome Therapeutics market to develop novel therapies which will drive the Dry Eye Syndrome treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dry Eye Syndrome Report Key Insights

1. Dry Eye Syndrome Patient Population
2. Dry Eye Syndrome Market Size and Trends
3. Key Cross Competition in the Dry Eye Syndrome Market
4. Dry Eye Syndrome Market Dynamics (Key Drivers and Barriers)
5. Dry Eye Syndrome Market Opportunities
6. Dry Eye Syndrome Therapeutic Approaches
7. Dry Eye Syndrome Pipeline Analysis
8. Dry Eye Syndrome Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Dry Eye Syndrome Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Dry Eye Syndrome Competitive Intelligence Analysis
4. Dry Eye Syndrome Market Overview at a Glance
5. Dry Eye Syndrome Disease Background and Overview
6. Dry Eye Syndrome Patient Journey
7. Dry Eye Syndrome Epidemiology and Patient Population
8. Dry Eye Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Eye Syndrome Unmet Needs
10. Key Endpoints of Dry Eye Syndrome Treatment
11. Dry Eye Syndrome Marketed Products
12. Dry Eye Syndrome Emerging Therapies
13. Dry Eye Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Dry Eye Syndrome Market Outlook (7 major markets)
16. Dry Eye Syndrome Access and Reimbursement Overview
17. KOL Views on the Dry Eye Syndrome Market
18. Dry Eye Syndrome Market Drivers
19. Dry Eye Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Dry Eye Syndrome Market report here: https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.